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resumo 
 
A espinal medula de mamíferos adultos não possui capacidade de 
regeneração ao contrário do nervo periférico lesionado. De forma a 
compreender os mecanismos que potenciem a regeneração do sistema 
nervoso central, o modelo de lesão condicionante foi usado. Neste, uma lesão 
no ramo periférico dos neurónios da raiz dorsal cerca de uma semana antes de 
uma lesão no ramo central dos mesmos neurónios, promove a regeneração do 
último. Através de abordagens proteómicas concluiu-se que a Glycogen 
Synthase Kinase 3β (GSK3β) e proteínas que interagem com esta, estavam 
diferencialmente regulados após lesão condicionante, explicando 
possivelmente o maior potencial regenerativo nesta condição. Com este 
projecto, pretendemos compreender o mecanismo de regulação da GSK3β 
que leva à regeneração axonal. Primeiro observámos nos neurónios da raiz 
dorsal, um aumento da fosforilação da Akt (a cinase que inactiva a GSK3β 
através de fosforilação da S9), um aumento da pGSK3β(S9)  (forma inactiva) e  
diminuição dos níveis de pGSK3β(Y216) (forma activa) após lesão 
condicionante validando os resultados da proteómica. Relativamente à espinal 
medula (local de lesão), verificou-se a diminuição de pGSK3β(Y216) após 
lesão condicionante em comparação com a lesão na espinal medula sugerindo 
que a GSK3β se encontra inibida após lesão condicionante por modulação 
deste resíduo. Relativamente aos substratos da GSK3β, na espinal medula a 
fosforilação do CRMP2 encontra-se diminuída e os níveis de pMAP1b 
encontram-se aumentados após lesão condicionante. De forma a perceber o 
papel da fosforilação da GSK3β(Y216) na regeneração axonal tratámos 
culturas de neurónios da raiz dorsal condicionados com ácido lisofosfatídico, 
um indutor da fosforilação da GSK3β(Y216), o qual reduziu o efeito de 
condicionamento. Para além disso, o inibidor VII (inibidor da GSK3) provocou 
um aumento da extensão axonal em neurónios adultos da raiz dorsal 
possivelmente por diminuição da fosforilação da GSK3β(Y216). Analisámos 
também o mecanismo responsável pela modulação da fosforilação da 
GSK3β(Y216). Os nossos resultados sugerem que a Fyn seja um bom 
candidato, uma vez que observámos na espinal medula níveis aumentados da 
forma inactiva da Fyn após lesão condicionante. De forma a determinar o 
papel da GSK3β in vivo, a regeneração axonal foi avaliada utilizando ratinhos 
GSK3βS9A knockin (KI). Tanto as culturas de neurónios da raiz dorsal de 
ratinhos GSK3βS9A KI não lesionados como após condicionamento, tiveram 
crescimento axonal semelhante à dos ratinhos wild type mostrando que a 
modulação da GSK3β através de fosforilação da GSK3β(S9) não é necessária 
para o efeito de condicionamento. Os nossos resultados sugerem que a 
fosforilação da GSK3β(Y216) tem um papel importante na regeneração axonal 
apesar de a literatura se focar no mecanismo inibitório da fosforilação da 
GSK3β(S9). A identificação da importância que a GSK3β possa ter no 
potenciamento da regeneração axonal após lesão condicionante, pode ser 
positiva no desenvolvimento de novas terapias para lesões na espinal medula. 
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abstract 
 
The adult mammalian spinal cord fails to regenerate, contrarily to the injured 
peripheral nerve. In order to shed light on the mechanisms enabling central 
nervous system axonal regeneration, the conditioning lesion model was used. 
In this model, an injury in the peripheral branch of the dorsal root ganglia 
(DRG), approximately one week prior to an injury in the central branch of the 
DRG, promotes regeneration of the latter. To identify putative candidates 
differentially regulated in the DRG following conditioning lesion in comparison 
to spinal cord injury (SCI) alone, two proteomic approaches were used. From 
these analysis, Glycogen Synthase Kinase 3β (GSK3β) and interacting 
proteins, were identified as being differentially regulated following conditioning 
lesion, possibly explaining the increased regeneration in this condition. In this 
study we aimed to understand how GSK3β is modulated in order to promote 
axonal regeneration. We observed in the DRG increased levels of pAkt (the 
kinase that inactivates GSK3β through S9 phosphorylation), an increase of 
pGSK3β(S9)  (inactive form) and decreased pGSK3β(Y216) (active form) levels 
in the conditioning lesion model, validating the proteomic results. Concerning 
the spinal cord injury site, we observed a decrease in pGSK3β(Y216) after 
conditioning lesion when compared to SCI, suggesting that the GSK3β activity 
is downregulated through modulation of this residue. Regarding the GSK3β 
substrates, CRMP2 phoshorylation levels are decreased and MAP1b is 
increasingly phosphorylated following conditioning lesion when compared with 
SCI alone in the spinal cord injury site. In order to evaluate the role of 
GSK3β(Y216) phosphorylation in axonal regeneration we treated conditioned 
DRG neurons with lysophosphatidic acid, an inducer of Y216 phosphorylation, 
which reduced the conditioning effect. On the other hand, the GSK3 inhibitor 
VII increased axon growth of adult DRG neurons possibly through a decrease 
of GSK3β(Y216) phosphorylation. We also analysed the mechanism 
responsible for the modulation of GSK3β(Y216) phosphorylation. Our results 
suggest that Fyn is a good candidate as we observed increased levels of the 
inactive form of Fyn after conditioning lesion in the spinal cord injury site. To 
evaluate the role of GSK3β in vivo, we assessed axonal regeneration in 
GSK3βS9A knockin (KI) mice. Both uninjured and conditioned DRG neuronal 
cultures from GSK3βS9A KI mice had similar neurite outgrowth to cultures 
performed with wild type mice showing that modulation of GSK3β through 
GSK3β(S9) phosphorylation is not required for the conditioning effect. In 
summary, our results suggest that GSK3β(Y216) phosphorylation has an 
important role in axonal regeneration, though the literature focuses on the 
inhibitory mechanism of GSK3β(S9) phosphorylation. Determining the role of 
GSK3β in the promotion of axonal regeneration after conditioning lesion, might 
impact in the development of new therapies for SCI. 
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Introduction 
 
1. Central nervous system (CNS) versus peripheral nervous system (PNS) 
regeneration: extrinsic and intrinsic factors 
 
Spinal cord injury (SCI) disrupts the connections between the brain and spinal cord, often 
resulting in the loss of sensory and motor function below the lesion site [1]. 
Understanding why CNS injured axons cannot regenerate after injury in adult mammals 
has been a major challenge [2]. The reduced intrinsic growth capacity of adult CNS 
neurons and the poor environment for axon extension, greatly contribute to the failure of 
CNS axonal regeneration (Figure 1A) [3], resulting in persistent or permanent disabilities 
of varying degrees of severity [4]. In fact, the growth capability of CNS neurons to 
elongate axons is markedly reduced during neuronal maturation [3]. Moreover, multiple 
models have now demonstrated that besides being a mechanical barrier, the molecular 
composition of the glial scar that is formed after a lesion in the CNS, as well as the 
production of inhibitory molecules by astrocytes, contribute for unsuccessful 
regeneration [5]. Compared to the CNS, peripheral axons can and do regenerate, (Figure 
1B) resulting in functional recovery when they succeed in reinnervating their targets [6, 
7]. Faster and more extensive Wallerian degeneration in the PNS may account for this 
relatively successful regeneration [8]. This raises the hope that understanding the 
mechanisms underlying PNS regeneration may lead to new approaches to enhance repair 
in refractory neuronal populations [4]. The strategy is to improve the rate at which the 
axons regenerate, being that in mammalians, the rate of axonal elongation is determined 
by the rate of slow axonal transport [6]. 
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Figure 1: Different responses to injury in the peripheral (A) and central (B) nervous systems. Taken from 
[9]. 
     
1.1. Extrinsic mechanisms 
 
Initial neuronal responses to axon injury in both PNS and CNS are similar in that Wallerian 
degeneration begins at the distal segment of severed axons, whereas axonal sprouting 
occurs in the proximal segment. However, the extent and speed of these processes are 
very different, being that the peripheral axonal regeneration is rather successful 
compared to that in the CNS. In the PNS, Wallerian degeneration is fast; axon and myelin 
debris are promptly cleared by Schwann cells and macrophages. This active process 
seems to be attributable to a steady Na+-dependent extracellular Ca2+ entry and is 
followed by sprouting of the proximal part of axons, resulting in active growth cones at 
the tip of axons [8]. Schwann cells proliferate to form a Büngner band, that plays an 
important role in this process, with oriented Schwann cells and extracellular matrix (ECM) 
guiding regenerative peripheral nerves [10]. Moreover, Schwann cells secrete a variety of 
neurotrophic and neurotropic factors to support axonal regrowth and guidance [8]. 
Wallerian degeneration is known to be a prerequisite to ensure normal regeneration 
following nerve injury [11] as myelin-associated inhibitors (MAIs) including myelin-
associated glycoprotein (MAG), oligodendrocyte-myelin glycoprotein (OMgp), Nogo, and 
netrin1 potently inhibit CNS axonal regeneration. Curiously, MAG is expressed by both 
CNS oligodendrocytes and PNS Schwann cells [12]. Lack of neurotrophic factors may 
partly contribute to the regenerative failure in adult CNS [3]. Besides this, the role of 
B 
A 
A 
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inflammation in CNS repair has been associated with both protective and detrimental 
effects [13]. Currently there is no direct explanation as to the differential effects exerted 
by macrophage cells, although it has been proposed that under different conditions these 
cells may be expressing different phenotypes, which might depend on the timing of 
macrophage activation [14]. Additionally, dysfunctions of the process of reactive 
astrogliosis and scar formation have the potential to contribute to, or to be primary 
causes of, CNS disease mechanisms either through loss of normal functions or through 
gain of detrimental effects [15]. Traditionally thought to be a simple mechanical barrier, 
subsequent studies suggested that inhibitory extracellular matrix molecules such as 
tenascin, semaphorin 3 and chondroitin sulfate proteoglycans (CSPGs), among others are 
dramatically upregulated during the inflammatory stages after injury. CSPGs generated by 
astroglial scar around lesions strongly suppress axonal extension via unknown receptor(s) 
[5]. Axon guidance molecules semaphorin 3A, 5A, and ephrin-3(Eph)B/Eph-A4 may 
restrict axonal elongation in the injured CNS [3]. Nevertheless, it is important to mention 
that despite the overall negative connotation of reactive astrogliosis, it exerts numerous 
essential beneficial functions in neural protection and repair of CNS cells and tissue, in 
which scar formation lies in the extreme in terms of the severity of responses to CNS 
insults [15]. Finally, despite the inhibitory environment of the adult CNS, spontaneous 
regeneration and reorganization of axons are found in animal models of CNS injury. For 
example, spontaneous axon sprouting of the corticospinal tract is observed proximal to 
the SCI site. Moreover, a few damaged corticospinal axons can also regrow beyond the 
lesion site [16]. 
 
1.2. Intrinsic mechanisms 
 
Upon embryonic to adult transition, the intrinsic neuronal growth activity is repressed to 
allow for proper synaptic development, but injury to adult peripheral neurons is capable 
of reactivating the intrinsic growth capacity. Whether intracellular signaling mechanisms 
in the growth cones of regenerating axons resemble those in developing nervous system 
remains largely unknown [8]. 
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Recent studies revealed that simply removing extracellular inhibitory activities is 
insufficient for promoting successful regeneration in the adult CNS. Importantly, evidence 
from different species and different models is accumulating to support the notion that 
diminished intrinsic regenerative ability of mature neurons is a major contributor to 
regeneration failure [2]. Indeed, removing MAIs or molecules associated with glial scar 
formation, by genetic deletions or pharmacological inhibitors, only allows limited 
sprouting [17]. Actually, regrowth involves expression of regeneration-associated genes 
(RAGs) [2] and in fact in the case of dorsal column lesion, no significant upregulation of 
RAGs has been observed. On the other hand, the expression of RAGs following peripheral 
nerve injury is observed [18].  
The retrograde transport of injury signals (also called positive injury signals) is one of the 
essential cellular mechanisms leading to regeneration. Moreover, there is evidence of 
other injury signals such as injury-induced discharge of axonal potentials and interruption 
of the normal supply of retrogradely transported target-derived factors (also called 
negative injury signals). These 3 distinct signaling mechanisms may act in complementary 
and synergistic roles and coordination between them is necessary to regulate the 
appropriate genes to promote neuronal survival and increase the intrinsic growth state of 
injured neurons (Figure 2) [19]. The distinct types of retrograde signals elicited in axons 
upon injury, range from rapid action potential discharges to slower mechanisms 
dependent on molecular motors [4]. Rapid ion fluxes at the lesion site are possibly the 
first indication of damage in axonal integrity upon injury. Lesion causes an increase of 
Ca2+ in the axon which propagates a depolarizing response to the soma via activation of 
voltage-dependent sodium channels [4]. A transient and localized increase in axonal 
calcium caused by axotomy, induces localized proteolytic activity which is a necessary 
step in the cascade of events that leads to growth cone formation [20]. Calcium waves are 
also likely important for cytoskeletal rearrangement and growth cone formation, as long-
range intracellular Ca2+ signaling changes motility in migrating neurons by regulating RhoA 
distribution [4]. 
In vitro studies showed that electrical stimulation accelerates motor [21] and sensory [22] 
axon outgrowth and increases cyclic AMP (cAMP) levels in dorsal root ganglia (DRG) 
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neurons. However, electrical stimulation of CNS does not promote regeneration [23] 
suggesting that electrical stimulation alone is not sufficient to trigger a complete 
regenerative response [19]. Thus, rapid electrophysiological mechanisms are likely to play 
a role in the initial priming of an injured neuron for growth, but effective regeneration 
requires a second phase of signaling [4]. 
Work over the past ten years has confirmed that axons can synthesize proteins locally. 
Indeed, mature neurons use axonal mRNA translation to locally synthesize injury signals 
that are transported to the nucleus of injured neurons [24]. The positive injury signals 
identified so far share one common requirement: microtubule-dependent retrograde 
transport. Combined with a protection mechanism against phosphatases during 
transport, activation and retrograde transport of mitogen-associated protein kinases 
(MAPKs) might play an important role in regeneration. In addition to MAPKs, axonal injury 
activates several transcription factors through the local release of cytokines [19].  
Although interruption of normal supply of retrogradely transported cues represents 
another important mechanism to sense injury, little is known about this type of signaling. 
Once a neuron is connected with its target, the intrinsic neuronal growth activity must be 
repressed as above mentioned. In order to allow regeneration to occur, this repression 
must be released. Nevertheless, future studies are needed to explore the role of negative 
injury signals in axonal regeneration. Despite the fact that neurotrophins represent the 
ideal candidates, evidence for their role as negative signals following injury has not yet 
been established [19]. Importantly, treating neurons overnight with neurotrophins 
(priming) such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) 
is another means of stimulating cAMP production, not by inducing cAMP synthesis but 
instead, preventing its degradation. When neurons are primed, neurotrophins activate 
Trk receptors and extracellular signal-regulated kinase (Erk) [25] producing a transient 
inhibition of phosphodiesterase 4 (PDE4) activity, the main responsible for cAMP 
hydrolysis. This causes cAMP to accumulate until reaching a threshold level, sufficient to 
override inhibitory signals mediated by MAG, Nogo-A and OMgp when the neurons are 
subsequently plated on myelin [26]. However, neurotrophins cannot directly overcome 
inhibition by myelin, making them ineffective as a treatment for SCI. Cell-permeable 
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cAMP analogues are a more effective way of directly elevating intracellular cAMP levels, 
being dibutyryl cAMP (dbcAMP) one of the most widely used agents. Administration of 
dbcAMP alone overcomes inhibition by MAG and myelin. However, targeting downstream 
effectors of cAMP may be more specific and thus more effective in promoting 
regeneration. By using specific gene products, it may be possible to directly affect the 
cytoskeleton while avoiding detrimental side effects such as inflammation [25]. 
 
Figure 2: Signaling mechanisms. (1) injury-induced discharge of axonal potentials, (2) interruption of the 
normal supply of retrogradely transported trophic factors or negative regulators of neuronal growth from 
the target, and (3) retrograde transport of activated proteins emanating at the injury site, termed positive 
injury signals. Taken from [19]. 
  
2. The conditioning lesion (CL) model in axonal regeneration 
 
Axonal regeneration can be manipulated [6] by intrinsically changing neurons so that they 
no longer recognize myelin as inhibitory [27]. If the peripheral axonal branches of DRG 
neurons are injured prior to lesioning the central axonal branch, the neurons are primed 
into a growth state and regenerate their central branches through a SCI site [4]. It has 
been described that optimal regeneration is obtained when the peripheral lesion 
precedes the central lesion by 1 week, extending hundreds of micrometers beyond the 
site of injury [25]. This paradigm has been described as the conditioning lesion model and 
correlates with increased gene expression and protein synthesis in the neuronal cell body 
and an increased rate of slow axonal transport [6]. In fact, retrograde injury signals travel 
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from the peripheral injury site back to the cell body to increase the intrinsic growth 
capacity of the neuron, enabling centrally injured neurons to regenerate. The 
conditioning injury suggests that distinct signaling mechanisms regulate responses to 
central versus peripheral injury in DRG neurons and may contribute to their different 
abilities to axonal regrowth [19]. Indeed, in one study all the tested RAGs were 
upregulated multiple fold in DRG neurons conditioned before the CNS lesion [18]. 
Interestingly, a similar upregulation was induced in animals that were either conditioned 
2, 4, or 8 weeks after CNS lesion or that underwent peripheral lesion only, indicating that 
the temporal order of the central and peripheral lesions does not affect the degree of 
upregulation of RAGs. Actually, DRG neurons conditioned after SCI also acquire the ability 
to grow but only in absence of traumatic tissue [28]. For both pratical and ethical reasons, 
this finding is extremely valuable, as a priming injury in the peripheral nerve cannot  be 
inflicted in humans to encourage growth of spinal axons [29]. 
Primary sensory neurons with cell bodies in the DRG are a useful model to study the 
mechanisms that regulate regeneration. DRG neurons are pseudobipolar neurons and 
possess 2 axonal branches: a peripheral axon that regenerates when injured and a 
centrally projecting that does not regenerate following injury. Remarkably, lesion in the 
peripheral branch before injury to the central branch promotes regeneration of central 
axons (Figure 3) [19]. The sciatic nerve (SN) is a commonly used model system for 
regeneration studies, comprising a mixed population of motor and sensory axons. The 
sensory neurons extending into the SN are located in the lumbar 4 (L4), L5 and L6 DRG 
that innervate skin and muscle of the hind limb [4]. 
Two of the conditioning lesion (CL) hallmarks is that the speed at which axons regenerate 
is manipulated and it raises the cAMP levels in DRG neurons similarly to what occurs in 
embryonic DRG neurons; a time of intense and rapid axonal growth [6]. Injections of 
cAMP analogues such as dbcAMP allows the axons to overcome myelin inhibition both in 
vitro and in vivo, mimicking the conditioning lesion (CL) effect. However, an important 
distinction has to be made between these two strategies. Although dbcAMP can 
overcome CNS inhibition of elongation, it does not increase the intrinsic growth state as 
conditioning lesion (CL) does [30]. 
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It is now known that the effects of cAMP are initially transcription independent (and 
protein kinase A (PKA)-dependent), causing the activation of PKA and later they become 
transcription dependent (and PKA-independent), by activation of cAMP response element 
binding (CREB) which leads to upregulated expression of genes such as arginase 1 (Arg1) 
and interleukin-6 whose products have been shown to directly promote axonal 
regeneration, overcoming myelin inhibition [25]. In particular, overexpression of Arg1 is 
sufficient to overcome inhibition by MAG [31]. 
 
 
Figure 3: Conditioning injury paradigm. Sensory axons in the adult spinal cord do not regenerate after 
injury (a), while peripheral injury results in a robust regenerative response. Regeneration of the central 
branch can be greatly enhanced by a previous injury to the peripheral branch, referred to as a ‘conditioning 
injury’ (b). Taken from [19]. 
 
3. Cytoskeleton rearrangement 
 
Neuronal growth cones are the machinery for detecting the environment for growth and 
guidance signals and also the major driving force for axonal elongation [8]. In fact, growth 
cones guide axons through appropriate routes, to locate a suitable synaptic partner 
(pathfinding), by activation of receptors for guidance molecules in their plasma 
membrane [32]. This ‘road’ comprises adhesive molecules that are either presented on a 
neighbouring cell surface (for example, transmembrane cell adhesion molecules (CAMs)) 
or assembled into a dense ECM. Additionally, anti-adhesive surface-bound molecules can 
prohibit the advance of the growth cone [33]. Finally,  these molecules may be 
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encountered as a concentration gradient that diffuses from an intermediate or final 
target source, presenting further steering instructions to the travelling growth cone [34]. 
Contrarily to what was previously thought, it is now known that the response to 
attraction or repulsion is not due to the intrinsic property of the cue, but instead to the 
specific receptors and internal signaling milieu of the growth cone [33]. The activation of 
receptors for guidance molecules in growth-cone plasma membranes drives intracellular 
signaling pathways that converge mainly at the growth-cone cytoskeleton [35]. 
Interestingly, the route that the growth cone must take to pathfind is rarely a straight 
one. Growth cones must make steering manoeuvres to change direction in choice points, 
and consequently reorganize the growth-cone cytoskeleton [32]. 
 
3.1. Structure of the growth cone and axon outgrowth 
 
The structure of the growth cone depicted on Figure 4 is fundamental to its function [33]. 
The filopodia are the first part of the growth cone coming into contact with guidance 
molecules and thus having an important role in axon guidance [36]. Filopodia stabilize 
when they encounter an attractive guidance molecule and retract when on contact with a 
repellent one [32]. In between the filopodia lie sheets of membrane called lamellipodia-
like veils [33]. The growth cone can be separated into three domains based on 
cytoskeletal distribution [37]. In the peripheral (P) domain, the organization of actin 
filaments (F-actin) is different in lamellipodia and filopodia. Lamellipodia are composed of 
branched dendritic actin network, whereas filopodia have parallel bundles of F-actin [32]. 
Additionally, individual dynamic microtubules explore this region, usually along F-actin 
bundles [33]. The central (C) domain comprises dynamic microtubules that extend into 
the P domain in addition to vesicles and numerous organelles, such as mitochondria and 
reticulum. A subset of microtubules in the C domain entering the growth cone from the 
axon shaft are relatively stable and generally restricted to this domain [32]. Finally, the 
transition (T) zone lies at the interface between the P and C domains, where actin arcs 
(actomyosin contractile structures) locate perpendicular to F-actin bundles [38]. The 
10 
 
dynamics of these cytoskeletal components determine growth cone shape and 
movement [33]. 
 
 
Figure 4: The structure of the growth cone. Taken from [33]. 
 
Actually, the growth cone engages its cytoskeleton to progress through three stages: 
protrusion, engorgement and consolidation [37] (Figure 5). The receptors in the distal end 
of the growth cone bind to an adhesive substrate, activating intracellular signaling 
cascades which result in the linkage between the substrate and actin [33]. Protrusion 
corresponds to the extension of lamellipodia and filopodia at the axon tip through actin 
filament polymerization which might be regulated by microtubules [39]. During 
engorgement, F-actin arcs reorientate towards the site of new growth and guide the C 
domain microtubules to advance and invade protrusions, carrying also membrane vesicles 
and organelles [33, 39]. Finally, consolidation occurs as the proximal part of the growth 
cone assumes a cylindrical shape and transport of organelles becomes bidirectional, thus 
forming a new segment of axon shaft [37]. The myosin II-containing arcs compress the 
microtubules into the newly localized C domain [33]. These three continuous stages occur 
during the formation of nascent axons, as well as during axon branching when new 
growth cones form from an axon shaft [37]. 
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Figure 5: Description of the axon outgrowth stages: protrusion, engorgement and consolidation. Taken 
from [33]. 
 
3.2. The growth-cone cytoskeleton 
 
Two cytoskeletal filaments invariably present in the growth cones are microtubules and 
actin [32]. The cytoskeleton and associated motor proteins play a critical role in axonal 
retrograde transport with microtubules being particularly relevant because they provide 
long-range tracks for transport and are mostly uniformly oriented in axons with plus ends 
towards the terminals and minus ends towards the cell body [4]. At the plus end, tubulin 
assembly takes place preferentially. However, there is some evidence for anterograde 
transport probably mediated by the dynein motor complex [32]. 
Microtubules are cylindrical polarized structures composed of linear arrays of alternating 
α- and β-tubulin subunits associated laterally, forming protofilaments [33, 39]. 
Microtubules are dynamic tubulin polymers that switch between growing and shrinking 
phases, a process known as dynamic instability, characterized by the rate of 
polymerization and depolymerization and the frequencies of catastrophes (transitions 
from polymerization to depolymerization) and rescues (transitions from depolymerization 
to polymerization) [39]. Several proteins bind to microtubules: some proteins stabilize 
microtubules (for example, microtubule-associated protein 1B (MAP1b)) [33], some act as 
microtubule motors (for example, dynein and kinesin) [40] and others are part of a family 
12 
 
called plus-end tracking proteins (+TIPs), which have been implicated in dynamic control 
of plus end microtubules and linking microtubules with actin- or membrane-associated 
structures (for example, adenomatous polyposis coli (APC)) [41]. 
Actin filaments are also polarized, with a barbed end (plus end) pointing towards the cell 
membrane where monomeric actin is generally assembled near/at the tip of filopodium 
and a pointed end (minus end) [32]. Their formation, stability and destruction are 
carefully regulated at every stage in the growth cone [33]. In fact, the plus end addition of 
globular(G)-actin produces a force that moves the F-actin bundle rearwards designated by 
retrograde flow. On the other hand, orthograde flow consists on the force on the plasma 
membrane that extends the filopodium [32]. Which mechanism predominates depends 
partly on the strength of the adhesion of the filopodium to the substratum where the 
growth cone is growing on [42]. 
It is now suggested that there is a physical interaction between F-actin and microtubules. 
Whether this is a direct interaction or mediated by specific proteins has not been 
determined [32]. Actually, actin has a pivotal role in determining microtubules localization 
in the growth cone [43]. Microtubules extend further into P domain when F-actin 
retrograde flow is attenuated and less successfully when retrograde F-actin flow is 
increased [32]. Moreover, distinct classes of actin structures seem to regulate different 
populations of microtubules. Whereas F-actin bundles can inhibit the protrusive activities 
of P domain microtubules when they are coupled together, F-actin arcs regulate the 
engorgement and consolidation activities of C domain microtubules [33]. 
 
3.3. Microtubules organization and axonal regeneration 
 
After injury, the formation of a growth cone at the tip of a transected axon is crucial for 
the subsequent axonal regeneration. The tips of lesioned axons located in the PNS 
transform into growth cones capable of sustained growth. The growth cone efficiently 
uses membrane trafficking, energy and an intact cytoskeleton for elongation. Stable 
microtubules are aligned in parallel bundles and serve as tracks for organelle transport to 
support the rapidly advancing growth cone and to form the backbone of the growing 
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axon. On the other hand, lesioned CNS axons form characteristic swellings at their tips 
known as retraction bulbs, which lack a regenerative response [44]. These differences 
underlie distinct cytoskeleton dynamic rearrangements which are essential for axon 
outgrowth [37]. Remarkably, in vivo growth cones contain bundled dynamic microtubules 
that reach the axonal tip whereas the dynamic microtubules are mislocalized in retraction 
bulbs. Frank Bradke and collaborators have shown that retraction bulbs are characterized 
by accumulated organelles (including trans-Golgi-derived vesicles and mitochondria) and 
dispersed microtubules compared with unlesioned axons and growth cones. Indeed, they 
concluded that destabilization of microtubules was sufficient to cause formation of 
structures reminiscent of retraction bulbs. Contrarily, they observed that stabilization of 
microtubules precludes the formation of retraction bulbs and is sufficient to induce 
elongation of CNS axons after lesion [44]. 
 
Figure 6: Model for retraction bulb formation versus growth cone-mediated regeneration. A, D, Before 
injury, PNS and CNS axons are connected to their targets and are functional. B, A few days after injury, the 
CNS axon proximal to axotomy responds to injury by forming a retraction bulb, which is characterized by 
dispersed microtubules and accumulated organelles. Stabilization of the microtubules starting immediately 
after CNS injury, inhibits the formation of retraction bulbs and may induce axon outgrowth. E, The PNS axon 
forms a growth cone after a lesion which allows for axon elongation. Destabilization of microtubules at this 
stage can convert the growth cones into retraction bulb-like structures. C, A few weeks after injury, the 
retraction bulb still enlarges with the accumulation of organelles. F, In contrast, the PNS axon continues its 
elongation until connecting to the target. Taken from [44]. 
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4. Glycogen synthase kinase 3β (GSK3β) as a putative candidate in axonal 
regeneration 
 
GSK3 proteins are serine/threonine kinases that were originally identified as key 
regulatory enzymes in glucose metabolism, phosphorylating glycogen synthase 
downstream of insulin signaling. There are two mammalian GSK3 isoforms, GSK3α and β, 
showing high sequence homology with each other across species; 85% total and 95% 
kinase domains homology [45, 46]. In rodents and humans an alternative splice variant of 
GSK3β – GSK3β2 has been reported, specifically expressed in the nervous system [46]. 
Although the name suggests functions restricted to glycogen synthesis, recently GSK3 has 
emerged as a fundamental regulatory kinase in the nervous system, ranging from neural 
development to mood stabilization and neurodegeneration [47]. Actually, changes in 
GSK3 activity have been associated with many psychiatric and neurodegenerative 
diseases such as Alzheimer’s disease, schizophrenia and autism spectrum disorders. 
Importantly, it has become more evident that GSK3 might be a common therapeutic 
target for different classes of psychiatric drugs [48]. Understanding how GSK3 is regulated 
could shed light on related signaling pathways and possible therapeutic applications of 
this kinase. 
GSK3 has been demonstrated as a key downstream regulator in signaling pathways 
engaged by many extracellular cues including Wnts, NGF, epidermal growth factor (EGF) 
and hedgehog [45]. Unlike many other kinases, GSK3β is usually active in resting cells [47] 
being activated by phosphorylation of the Y216 residue and inactivated through S9 
phosphorylation [49]. Upon activation of the phosphoinositide 3-kinase (PI3K) signaling 
pathway by neurotrophins, GSK3β is inactivated by Akt/protein kinase B (PKB) through 
phosphorylation of the S9 residue in its amino-terminal region. Factors that inhibit axon 
growth, such as semaphorin 3A, activate GSK3β by inhibiting S9 phosphorylation. Other 
special feature of GSK3β is that it phosphorylates substrates that have been ‘primed’ by 
other kinases [47]. Many GSK3 substrates are microtubule-associated proteins (MAPs) 
including APC, collapsin response mediator protein 2 (CRMP2), MAP1b, microtubule-
associated protein (MAP2), tau, neurofilament and kinesin light chain [45]. Both APC and 
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CRMP2 are examples of ‘primed’ substrates. The ability of CRMP2 to bind to tubulin 
dimers is abolished when it is phosphorylated by GSK3β [50]. Similarly, phosphorylation 
of APC by GSK3β prevents its ability to bind to microtubules. Thus, inactivation of GSK3β 
results in CRMP2 and APC dephosphorylation, which leads to microtubule polymerization 
and stabilization, respectively. On the other hand, MAB1b is thought to be an unprimed 
substrate [47]. GSK3β is activated by neurotrophins via the ERK pathway and, 
phosphorylation of MAP1b by GSK3β positively regulates actions of the first, namely 
ensuring microtubule dynamics [45, 47]. Inhibition of GSK3β activity abolishes MAP1b 
phosphorylation and reduces microtubule dynamics [47]. Remarkably, it has been shown 
that phosphorylated MAP1b co-localizes with dephosphorylated APC and CRPM2 at the 
distal ends of growing axons [47, 51]. There is emerging evidence that S9 phosphorylation 
has little effect on GSK3β activity towards substrates that do not require ‘priming’ [52]. 
Thus, GSK3β may phosphorylate MAP1b and maintain microtubule dynamics even when 
it is phosphorylated at S9 [47]. This implies that GSK3β can simultaneously activate some 
substrates and inactivate others, which indicates that when phosphorylated on S9, GSK3 
is only partially inactivated. This mechanism provides coordinated regulation of 
microtubule polymerization, stabilization and dynamics which ensures optimal 
microtubule assembly in axons. It is presumed as well that GSK3β almost certainly 
regulates actin filaments [47]. 
Studies in hippocampal neurons show that the inactive form of GSK3β is located at the tip 
of each neurite before polarization, but when neurons begin to polarize and one of these 
neurites develops into the axon, pGSK3β becomes concentrated at the axonal tip. This 
suggests that local inactivation of GSK3β at the nascent axon is fundamental for 
polarization [50]. However, recently a mutant mice (GSK3αS21A/GSK3βS9A double 
knockin (KI) mice) did not show overt phenotype in the nervous system, in particularly 
they developed normal neuronal polarity [53]. This suggests that alternative pathways 
might regulate GSK3 activity. Studies so far have concerned the inhibitory mechanism of 
GSK3. Nevertheless, it is becoming increasingly apparent that activation of GSK3 is an 
important aspect [46]. In fact, besides the crucial role attributed to S9 phosphorylation, 
Y216 might have an essential role on GSK3β regulation (Figure 7). Tyrosine 
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phosphorylation is thought to occur by signal-dependent regulation or through 
autophosphorylation, facilitating GSK3 activity by promoting substrate accessibility [46]. 
As a matter of fact, in mammalian cells, the tyrosine kinases Fyn, Pyk2 and Csk have been 
implicated in GSK3 phosphorylation. Pyk2 is thought to mediate lysophosphatidic acid 
(LPA)-induced activation of GSK3 by phosphorylation on Y216 residue, during neurite 
retraction [54]. On the other hand, Cohen and coworkers clearly show that Y216 
phosphorylation is an autophosphorylation event [55]. 
It has been observed that strong inhibition of GSK3 activity dramatically reduces axon 
growth in immature and adult DRG neurons. In contrast, incomplete GSK3 inactivation 
increased axon length[3]. It seems that GSK3 activation contributes to axon growth 
repression, but a degree of GSK3 activity is necessary for efficient axon extension because 
of the dual roles of GSK3 in activating and inactivating different substrates during 
microtubule assembly [45]. Recently, Dill and his collaborators claimed that inactivation 
of GSK3β stimulates significant neurite elongation and axonal growth in vitro and 
promote axonal regeneration and functional recovery in vivo after traumatic CNS axonal 
injuries [3]. Nevertheless, a lot of debate is still going on which role GSK3β performs in 
axonal regeneration, as some reports describe inactivation of GSK3β as causing neurite 
outgrowth inhibition in cerebellar and DRG neurons, mimicking the inhibitory effects of 
myelin [56]. Actually, Alabed and coworkers propose a model in which GSK3 myelin-
dependent inactivation by S9 phosphorylation, causes collapsin response-mediated 
protein 4 (CRMP4) dephosphorylation and consequently enhancing L-CRMP4-RhoA 
interaction, that mediates the inhibitory effects. 
Most of the members of GSK3β pathway were recently detected in our laboratory, with a 
fold change CL/SCI compatible with a crucial role of GSK3β in the gain of regenerative 
capacity following conditioning lesion (CL). This identification was performed recurring to 
proteomic screening based on phosphoproteomics by Kinexus arrays, which enables to 
identify and quantify phosphorylating proteins in key signaling pathways, and iTRAQ 
(isobaric tag for relative and absolute quantitation), that enables the identification and 
quantification of proteins from different sources in a single experiment, following a non-
gel based approach. 
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Figure 7: Representation of the three aspects of microtubule assembly in axons, regulated by GSK3β: 
microtubule polymerization, stabilization and dynamics. In the PI3K pathway, Akt inactivates GSK3β by S9 
phosphorylation, which in turn dephosphorylates CRMP2 and APC. This promotes microtubule 
polymerization and stabilization. In the Ras pathway, ERK phosphorylates and activates GSK3β which will 
phosphorylate MAP1b leading to microtubule dynamics enhancement. These three aspects act together to 
establish optimal axonal microtubule assembly. 
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Objectives 
 
The main objective of this work was to understand how GSK3β is regulated in order to 
ultimately promote axonal regeneration. To achieve this goal, the following strategies 
were pursued: 
 
1. Validate the modulation of the GSK3β pathway in the conditioning lesion (CL) model 
2. Evaluate the role of GSK3β Y216 phosphorylation in axonal regeneration 
3. Identify the mechanism responsible for the modulation of Y216 phosphorylation 
4. Determine the role of GSK3β regulation in vivo using GSK3βS9A KI mice 
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Materials and Methods 
 
Surgical procedures 
 
Rats were handled according to European Union and National rules. All animals were 
maintained under a 12h light/dark cycle and fed with regular rodent’s chow and tap 
water ad libitum. In order to perform the lesions described below, Wistar rats with ≈8-10 
weeks old were used. 
 
Sciatic nerve injury: animals were anesthesized with a mixture of ketamine and 
medetomidine (0,5mg/kg of medetomidine and 75mg/kg of ketamine). The skin was 
shaved, the sciatic nerve was exposed and a transection at the level of the mid-thigh was 
performed with a scissor. Analgesia was performed 48h following injury, with 
buthorphenol, 1mg/kg twice a day. 
 
Spinal cord hemisection: animals were anesthesized with ketamine/medetomidine as 
mentioned above. Spinal cord hemisection at the dorsal thoracic (T7) level was performed 
with a microscissor. The postoperative treatment consisted of subcutaneous injection of 
buthorphenol 1mg/kg twice a day for 72h (analgesia); daily subcutaneous injection of 5ml 
of Duphalyte for 72h (fluid therapy) and manual voiding of the bladder twice a day during 
the time of the experiment. Wet food was placed in the cage floor and water with 
antibiotic (0,016% baytril) was supplied in long nipple bottles. 
 
Conditioning lesion animals: animals were subjected to sciatic nerve transection followed 
by spinal cord hemisection approximately 1 week later. 
 
Primary cultures of DRG neurons 
 
DRGs were aseptically dissected, freed of roots and treated with 0,125% collagenase 
(Sigma) for 90 min at 37°C with 5%CO2. After enzyme treatment, a single-cell suspension 
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was obtained by trituration with a fire-polished Pasteur pipette. The cell suspension was 
centrifuged into a 15% albumin gradient for 10 min at 10000g. The resulting pellet was 
resuspended in DMEM/F12 medium (Sigma) supplemented with B27  (Invitrogen) and 50 
ng/ml of nerve growth factor (Milipore), plated in poly-L-lysine/laminin coated 13mm 
coverslips and maintained at 37°C with 5%CO2. 
 
Neurite outgrowth of DRG neuron cultures 
 
DRG neuron cultures were performed as described previously. To determine the neurite 
outgrowth of DRG neurons in the presence of LPA (Sigma), lumbar (L4-L6) DRG neurons 
from animals with sciatic nerve injury were cultured for 8h at 37°C. LPA (100μM) was 
added 1h before ending the cultures. In order to evaluate the effect of GSK3 inhibitors, 
neurite outgrowth of uninjured DRG neurons cultured for 15h in the presence of different 
inhibitors was performed. Inhibitor α-4-dibromoacetophenone or inhibitor VII (1μM and 
10μM, Calbiochem), inhibitor 6-bromoindirubin-3’-oxime or inhibitor X (30nM and 
300nM, Calbiochem) and inhibitor SB415286 (7,5μM and 50μM, Sigma) were used. 
After fixation with 4% paraformaldehyde (PFA), cells were immunostained with βIII-
tubulin. Briefly, cells were permeabilized with Triton-X 100, blocked in blocking buffer (5% 
fetal bovine serum, 0,4% Tween-20 in PBS) for 1h at room temperature and incubated 
with the primary antibody anti βIII-tubulin (1:2000, Promega) in blocking buffer overnight 
at 4°C. The cells were later incubated with Alexa488 anti-mouse IgG (1:1000, Invitrogen) 
in blocking buffer for 1h at room temperature and finally mounted with Vectashield with 
DAPI (Vector laboratories). Neurite outgrowth measurement was carried out from 20x 
magnified fields using Neuron J plugin for ImageJ, a public domain JAVA image-processing 
program. At least 100 cells were analysed for each condition. 
 
Neurite outgrowth of DRG neuron cultures from GSK3βS9A knockin mice 
 
GSK3βS9A knockin mice were kindly provided by Dario R. Alessi (MRC Protein 
Phosphorylation Unit, Dundee, Scotland) [57]. DRG neuron cultures were performed as 
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described previously and grown for 14 hours (uninjured neurons, Un) or kept in culture 
for 24 hours, treated with trypsin and grown for 14 hours (conditioned neurons, cDRG). 
Cells were then fixed for neurite outgrowth measurement, performed as above 
mentioned. 
 
Gene transfection 
 
The following constructs were used: GFP-tagged versions of kinase-dead Pyk2 (Pyk2 
K457A) were provided by Drs. Sancho and Sanchez-Madrid (Hospital de la Princesa, 
Madrid, Spain). GSK3βWT plasmid was kindly provided by Dr. Michal Hetman [58]. The 
GSK3βWT DNA fragment was excised from the plasmid with SmaI and XbaI and inserted 
into pEGFP-C1 (Clontech), which was used to produce the GSK3βY216F mutant (using the 
Quickchange kit; Stratagene). Mutants were constructed using two mismatched primers 
(5’-GGAGAGCCCAATGTTTCATTTATCTGTTCTCGGTACTAC-3’ and 5’-
GTAGTACCGAGAACAGATAAATGAAACATTGGGCTCTCC-3’). Minipreps of plasmid DNA 
were tested by sequencing at SEQLAB (Germany). 
DRG neurons from animals with SCI were transfected with the DNA constructs (EGFP; 
GSK3βY216F and Pyk2KD) according to the Amaxa protocol for mouse neurons. Briefly, 
dissociated neurons were spun down to remove the supernatant completely and 
resuspended in 100μl specified Amaxa electroporation buffer with 4μg plasmid DNA. 
Suspended cells were then transferred to a 2,0mm cuvette and electroporated with an 
Amaxa Nucleofector apparatus. After electroporation, cells were cultured in suspension in 
uncoated plastic wells for 24h and then transferred to poly-L-lysine/laminin coated 13mm 
coverslips and kept in culture for 16 hours. Cells were then fixed for neurite outgrowth 
measurement as previously described. 
 
Western blotting 
 
DRGs (L4-L6) from animals either uninjured, with SCI alone or conditioning lesion (CL) 
were collected. Samples of spinal cord (T7-T8) of uninjured animals or animals with SCI or 
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conditioning lesion (CL) were dissected. Protein lysates were prepared by homogenizing 
the tissues in Kinexus buffer (20mM MOPS, 2mM EGTA, 5mM EDTA, 30mM NaF, 60mM β-
glycerophosphate, 20mM sodium pyrophosphate, 1mM sodium orthovanadate, 1% Triton 
X-100, 1% DTT), 1mM PMSF and protease inhibitor cocktail (GE Healthcare). For cell 
lysates of DRG neurons, cultures were performed as described above and cells were lysed 
in Kinexus buffer with a cell scraper. After sonication, samples were centrifuged at 
15000gmax for 10min at 4°C. Total protein quantification was assessed using the Bio-Rad 
DC protein assay reagents. For Western blot of conditioned DRG cultures in the presence 
of LPA, DRG neurons were treated with LPA for 0, 5, 30 and 60 minutes. 
Protein lysates (25-50μg/lane) were run on 10% or 12% SDS-PAGE gel and then 
transferred to a nitrocellulose membrane (Amersham). For the anti-phospho-MAP1b and 
anti-MAP1b identification, Criterion XT Precast Gel 3-8% Tris-Acetate (Bio-Rad) was used. 
For Western analysis, membranes were blocked with blocking buffer (5% nonfat dried 
milk in TBS 0,1% Tween 20) and incubated overnight at 4°C in 5% BSA in TBS 0,1% Tween 
20 with primary antibodies. In the case of the CRMP2 Western blot, the membrane was 
incubated for 1h room temperature in 5% milk in TBS 0,1% Tween 20 with primary 
antibodies. The following primary antibodies were used: rabbit anti-phospho-Akt(S473) 
(1:2000, Cell Signaling), rabbit anti-Akt (1:1000, Cell Signaling), rabbit anti-phospho-
GSK3β(S9) (1:1000, Cell Signaling), rabbit anti-phospho-GSK3β(Y216) (1:2000, Santa Cruz 
Biotechnology), mouse anti-GSK3α/β (1:3000, Santa Cruz Biotechnology), rabbit anti-
phospho-Src(Y529) (1:500, Signalway antibody), rabbit anti-Fyn (1:1000, Cell Signaling), 
goat anti-Pyk2 (1:1000, Santa Cruz Biotechnology), sheep anti-phospho-
CRMP2(T509/514) (1:1000, Kinasource), sheep anti-CRMP2 (1:500, Kinasource), mouse 
anti-phospho-MAP1b(T1265) (1:500, Novus Biologicals), mouse total MAP1b (1:2500, 
kindly provided by Dr Itzhak Fischer, Drexel University College of Medicine) and mouse 
anti-GAPDH (1:2000, Santa Cruz Biotechnology). After washing, membranes were 
incubated with secondary antibodies for 1h at room temperature. The antibodies used 
were anti-rabbit HRP (1:10000, Jackson Immunoresearch), anti-mouse HRP (1:10000, 
Thermo Scientific) and anti-goat/sheep (1:20000, Binding Site). Proteins were detected 
using a chemiluminescent substrate, Pierce ECL Western blotting substrate (Thermo 
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Scientific). For each experiment representative Western blots are shown. Densitometry 
was performed with QuantityOne software (Bio-Rad). 
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Results 
 
5. Validation of GSK3β pathway in the conditioning lesion model 
 
Our group has previously performed a screening to search for protein candidates that 
could be responsible for the gain of CNS regeneration capacity in the conditioning lesion 
model. Two proteomic approaches, iTRAQ and Kinexus arrays (Kinetworks phospho-site 
broad coverage pathway screen) were used in order to identify altered proteins and 
phosphorylated forms of key signaling proteins in extracts of DRG from adult rats with 
conditioning lesion (CL) or spinal cord injury (SCI). Interestingly, several proteins 
belonging to GSK3β pathway were modified when comparing both groups, as can be 
concluded from the CL/SCI ratio represented in Table 1. However, these results required 
validation by additional techniques such as Western blotting. 
 
Table 1: List of proteins from the GSK3β pathway differentially regulated after conditioning lesion (CL) as 
determined by iTRAQ and Kinexus proteomics. 
 CL/SCI 
Protein kinase B alpha (Akt) [S473] Kinexus: 1,53 
Glycogen synthase kinase 3 beta (GSK3β) [S9] Kinexus: 1,55 
Glycogen synthase kinase 3 beta (GSK3β) [Y216] Kinexus: 0,53 
Collapsin response mediator factor 2 (CRMP2) iTRAQ: 0,83 
Microtubule associated protein 1b (MAP1b) iTRAQ: 0,80 
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5.1. GSK3β pathway is differentially regulated by the conditioning lesion in the 
DRG 
 
The first part of this project consisted on the validation of the GSK3β pathway in the 
conditioning lesion model given the differences observed in the DRG in the above 
mentioned proteomic approaches and considering the putative importance of GSK3β in 
the gain of regenerative capacity following conditioning lesion. For that, we performed 
Western blotting in the DRG, for proteins belonging to the GSK3β pathway differentially 
regulated according to iTRAQ and Kinexus. In addition to samples from animals with SCI 
or conditioning lesion, we analysed samples from uninjured animals to determine the 
protein alterations caused by the lesion. The levels of phosphorylated Akt (pAKT(S473); 
the kinase responsible for GSK3β(S9) phosphorylation) were similar between uninjured 
(Un) and SCI animals but the animals with conditioning lesion (CL) exhibited an increase in 
pAkt(S473) (Figure 8) which is in agreement with the Kinexus results. In what concerns to 
pGSK3β(S9) (the inactive form of GSK3β), we determined an increase in the conditioning 
lesion (CL) model, when compared to the SCI model and to the uninjured (Un) animals 
(Figure 9). This is in agreement with the differences observed for pAkt and also with the 
result obtained by Kinexus analysis. Concerning pGSK3β(Y216) (the active form of GSK3β), 
the phosphorylation of this protein in this particular residue is diminished in the 
conditioning lesion (CL), comparing to the SCI and to uninjured (Un) animals (Figure 10) 
which validates the result obtained by Kinexus. In respect to the GSK3β substrate CRMP2, 
we only assessed animals with SCI or conditioning lesion (CL). It has been described that 
CRMP2 contains two isoforms, CRMP2A (75kDa) and CRMP2B (64kDa) which share a 
common targeted epitope at the C-terminal end [59]. In the DRG, we were only able to 
quantify the CRMP2B isoform which showed a decrease after conditioning lesion (CL) 
when compared to the SCI model (Figure 11). The proteomic approach iTRAQ did not 
distinguish the two isoforms but showed a decrease of total CRMP2 after conditioning 
lesion (CL) in comparison with SCI only. These results validated the proteomic techniques 
used previously and suggest that after conditioning lesion, GSK3β activity diminishes in 
the DRG.  
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Figure 8: Akt(S473) is increasingly phosphorylated in the conditioning lesion model 
Western blot analysis (A) and respective quantification (B) of the relative amount of pAkt (S473) in DRG 
extracts of uninjured (Un), spinal cord injury (SCI) and conditioning lesion (CL) animals. Results are 
presented as mean±sem. Two-tailed Student’s t test with p<0,05 (*). 
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Figure 9: GSK3β(S9) phosphorylation is increased after conditioning lesion 
Western blot analysis (A) and respective quantification (B) of the relative amount of pGSK3β(S9) in DRG 
extracts of uninjured (Un), spinal cord injury (SCI) and conditioning lesion (CL) animals. Results are 
presented as mean±sem. Two-tailed Student’s t test with p<0,05 (*). 
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Figure 10: GSK3β(Y216) phosphorylation is downregulated in the conditioning lesion model 
Western blot analysis (A) and respective quantification (B) of the relative amount of pGSK3β(Y216) in DRG 
extracts of uninjured (Un), spinal cord injury (SCI) and conditioning lesion (CL) animals. Results are 
presented as mean±sem. Two-tailed Student’s t test with p<0,05 (*). 
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Figure 11: CRMP2B total levels are decreased after conditioning lesion 
Western blot analysis (A) and quantification (B) of the relative amount of CRMP2B in DRG extracts of spinal 
cord injury (SCI) and conditioning lesion (CL) animals. Results are presented as mean±sem. Two-tailed 
Student’s t test with p<0,05 (*). 
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5.2. The conditioning lesion leads to a decrease in GSK3β phosphorylation at 
Y216 in the spinal cord injury site 
 
The GSK3β pathway plays an important role in axonal regeneration by local regulation of 
the cytoskeletal dynamics of the growth cone. As such we evaluated GSK3β regulation in 
the spinal cord injury site. We observed that after injury there is a decrease of 
pGSK3β(S9) in the lesion site which is not altered by a conditioning lesion (CL) (Figure 12). 
In the case of Y216 phosphorylation, the levels of pGSK3β(Y216) are decreased after SCI. 
Compared with levels in animals with SCI, animals with conditioning lesion present 
decreased levels of pGSK3β(Y216) in the lesion site (Figure 13). Although the majority of 
research on GSK3β has focused on the inhibitory phosphorylation at S9, our data shows a 
decrease in the levels of pGSK3β(Y216) from animals with conditioning lesion when 
compared to animals with SCI. Moreover, no difference was observed in the amount of 
pGSK3β(S9) between these models. Together our results suggest that downregulation of 
GSK3β(Y216) phosphorylation in the lesion site might underlie the gain of regenerative 
capacity in the conditioning lesion model. In respect to the GSK3β substrates MAP1b and 
CRMP2, we only assessed animals with SCI or conditioning lesion (CL). Interestingly, we 
did not identify any phosphorylated MAP1b(T1265) after SCI, contrarily to the increase 
observed in the conditioning lesion (CL) in the injury site (Figure 14). Regarding CRMP2, as 
mentioned above two isoforms exist, but we were only able to quantify CRMP2A in the 
injury site. Our results show that in the spinal cord after conditioning lesion (CL), there is a 
decrease of the phosphorylated form of CRMP2A(T509/514) when compared to SCI 
(Figure 15). These results show that the decrease in GSK3β kinase activity due to 
downregulation of Y216 phosphorylation in the conditioning lesion (CL) model leads to a 
decrease in phosphorylation of CRMP2 which is required for axonal elongation. In the 
case of MAP1b, we only observed the phosphorylated form of the protein in the 
conditioning lesion (CL) model which is not in accordance with a decrease in GSK3β 
activity, but is in agreement with the fact that phosphorylated MAP1b is required for 
axonal growth. 
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Figure 12: GSK3β(S9) phosphorylation is increased after conditioning lesion 
Western blot analysis (A) and respective quantification (B) of the relative amount of pGSK3(S9) in spinal 
cord extracts of uninjured (Un), spinal cord injury (SCI) and conditioning lesion (CL) animals. Results are 
presented as mean±sem. Two-tailed Student’s t test with p<0,05 (*). 
 
 
 
 
0,00
0,40
0,80
1,20
Un SCI CL
p
G
SK
3
β
(Y
2
1
6
)/
G
SK
3
β *
*
*
pGSK3β(Y216)
GSK3β
GSK3β2
pGSK3β1
pGSK3β2
GSK3β1
Un SCICL
 
Figure 13: GSK3β(Y216) phosphorylation is downregulated in the conditioning lesion model 
Western blot analysis (A) and quantification (B) of the relative amount of pGSK3β(Y216) in spinal cord 
extracts of uninjured (Un), spinal cord injury (SCI) and conditioning lesion (CL) animals. Results are 
presented as mean±sem. Two-tailed Student’s t test with p<0,05 (*). 
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Figure 14: MAP1b(T1265) phosphorylation is upregulated in the conditioning lesion 
Western blot analysis (A) and quantification (B) of the relative amount of pMAP1b(T1265) in spinal cord 
extracts of spinal cord injury (SCI) and conditioning lesion (CL) animals. Results are presented as mean±sem. 
Two-tailed Student’s t test with p<0,05 (*). 
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Figure 15: CRMP2A(T509/514) phosphorylation is decreased after conditioning lesion 
Western blot analysis (A) and quantification (B) of the relative amount of pCRMP2(T509/514)  in spinal cord 
extracts of spinal cord injury (SCI) and conditioning lesion (CL) animals. Results are presented as mean±sem. 
Two-tailed Student’s t test with p<0,05 (*). 
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6. Evaluation of the role of GSK3β(Y216) phosphorylation in axonal 
regeneration 
 
6.1. Induction of Y216 phosphorylation decreases the conditioning effect in 
vitro 
 
The second part of this project intended to evaluate the role of GSK3β(Y216) 
phosphorylation in the promotion of axonal regeneration. We addressed this question by 
performing DRG cultures of conditioned DRG neurons (animals with SNI) in the presence 
of LPA, a compound that increases Y216 phosphorylation of GSK3β. With this approach 
we could answer the question whether a decreased phosphorylation of GSK3β at Y216 is 
required for the conditioning effect. 
Initially, we evaluated the phosphorylation status of Y216, by performing Western 
blotting of lysates from conditioned DRG cultures in the presence of LPA for the following 
time points: 0, 5, 30 and 60 minutes, unraveling that at 30 minutes, the phosphorylation 
of GSK3β(Y216) is maximal (Figure 16). Then, we performed neurite outgrowth to unravel 
the role of GSK3β(Y216) phosphorylation in the promotion of axonal regeneration by the 
conditioning effect. Representative pictures for uninjured (Un), conditioned DRG (cDRG) 
and conditioned DRG in the presence of LPA (cDRG+LPA) are presented in Figure 17. In 
agreement with the literature, the conditioning effect was observed, as determined by 
the increase in percentage of cells with neurites, mean length and length of the longest 
neurite for conditioned DRG (cDRG) in comparison with the uninjured (Un). Moreover, 
the branching (number of segments) decreases for conditioned DRG (cDRG) when 
compared to uninjured (Un). The LPA treatment decreased the percentage of cells with 
neurites and the mean length when compared to conditioned DRG (cDRG) (Figure 18). In 
order to elucidate better what happens in terms of axonal extension in our conditions, 
the length of the longest neurite was scored according to particular lengths and the 
corresponding percentage of cells with neurites was calculated. Again, we can see that 
the conditioning effect is working, as in the conditioned DRG (cDRG) we observed less 
smaller neurites (<100µm) and more longer ones (100-350µm and >350µm) than in the 
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uninjured (Un) animals. Addition of LPA to conditioned DRG (cDRG) caused a rise in the 
percentage of cells with smaller neurites and a decrease of intermediate and longer 
neurites (Figure 19).  
Our results suggest that a decrease in Y216 phosphorylation of GSK3β might have an 
important role in the promotion of axonal growth by the conditioning effect. 
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Figure 16: GSK3β(Y216) phosphorylation reaches maximum levels with LPA treatment for 30 min 
Western blot analysis (A) and respective quantification (B) of the relative amount of pGSK3β(Y216) present 
in lysates from conditioned DRG cultures. Results are presented as mean±sem. Two-tailed Student’s t test 
with p<0,05 (*). 
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Figure 17: Representative pictures of DRG cultures stained for βIII-tubulin. A. DRG cultures from uninjured 
animals (Un); B. DRG cultures from animals with SNI (cDRG); C. DRG cultures from animals with SNI, in the 
presence of 100μM LPA (cDRG+LPA).  
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Figure 18: Neurite outgrowth of DRG neurons from uninjured animals (Un) and animals with SNI grown in 
the absence (cDRG) or presence of 100μM LPA (cDRG+LPA).  The results are expressed as mean±sem. Two-
tailed Student’s t test with p<0,05 (*). 
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Figure 19: Percentage of cells with neurites for uninjured (Un), conditioned DRG (cDRG) and conditioned 
DRG in the presence of LPA (cDRG+LPA) which are scored according to: <100μm; 100-350μm or >350μm for 
the length of the longest neurite. 
  
 
6.2. Overexpression of GSK3βY216F in DRG neurons isolated from animals 
with spinal cord injury 
 
To further explore the relevance of GSK3β phosphorylation at Y216 in axonal growth, we 
analysed the effect of overexpressing GSK3βY216F in DRG neurons from animals with 
spinal cord injury. We had observed that animals with spinal cord injury present an 
increase in pGSK3β(Y216) in comparison with animals with conditioning lesion, so we 
hypothesized that mutation of the Y216 residue would increase the growth capacity of 
spinal cord injury neurons. DRG neurons were transfected with the control EGFP vector or 
with GSK3βY216F cloned into the EGFP vector. Representative images for each condition 
are shown on Figure 20. The percentage of cells with neurites was higher for the cells 
transfected with the EGFP-GSK3βY216F. Regarding the number of segments, the EGFP-
GSK3βY216F construct leads to an increase in the number of segments. When transfected 
with EGFP-GSK3βY216F, the cells present a decrease in the mean length. Concerning the 
total length, no statistically differences were observed between the two conditions. For 
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the length of the longest neurite, there is a decrease of the length of the longest neurite 
for the EGFP-GSK3βY216F construct (Figure 21). These results showing that 
overexpression of GSK3βY216F decreases neurite outgrowth suggest that a minimal 
kinase activity is required for the GSK3β effect in axonal growth. 
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Figure 20: Representative pictures of adult DRG cultures from animals with SCI stained for βIII-tubulin A. 
cells transfected with control EGFP vector; B. cells transfected with GSK3βY216F cloned into the EGFP 
vector.  
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Figure 21: Neurite outgrowth of DRG neurons from animals with SCI transfected with EGFP or EGFP-
GSK3βY216F. The results are expressed as mean±sem. Two-tailed Student’s t test with p<0,05 (*). 
 
 
6.3. Evaluation of the effect of GSK3β inhibition in the promotion of axonal 
regeneration by a decrease in Y216 phosphorylation 
 
Our results suggest that the conditioning lesion leads to a decrease in GSK3β activity 
which promotes axonal regeneration. Based on our observations which demonstrate a 
regulatory role of pGSK3β(Y216) on axonal growth and taking into account that global 
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inhibition of GSK3β inhibited axonal regeneration, we decided to analyse the effect of 
several GSK3β inhibitors on axonal growth and in parallel analyze the phosphorylation 
status of the protein for the inhibitors having an effect. We treated adult DRG neurons 
with the following inhibitors: SB415286, 6-bromoindirubin-3’-oxime (inhibitor X) and α-4-
dibromoacetophenone (inhibitor VII). Inhibitors were used at a low dose (to check for 
induction of growth) and at high dose (for inhibition of growth). In Figure 22 are shown 
representative images of DRG neurons in the presence of inhibitor SB415286. In fact, the 
only significant differences found for this experiment are related to the percentage of 
cells with neurites, which increases with the low dose of inhibitor, and to the mean length 
and length of the longest neurite, which present a decrease for the highest dose in 
comparison with the control (Figure 23). 
 
 
Figure 22: Representative pictures of adult DRG cultures stained for βIII-tubulin. A. DRG cultures in 0,1% 
DMSO (control); B. DRG cultures treated with inhibitor SB415286 7,5μM; C. DRG cultures treated with 
inhibitor SB415286 50μM. 
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Figure 23: Neurite outgrowth of adult DRG neurons grown in the absence (control) or presence of inhibitor 
SB (7,5µM and 50µM). The results are expressed as mean±sem. Two-tailed Student’s t test with p<0,05 (*). 
 
Regarding the inhibitor X, representative images are shown on Figure 24. For this GSK3 
inhibitor, no significant differences were found for any of the conditions. The only 
remarkable exception was the increase of the percentage of cells with neurites for 
inhibitor X 30nM and the decrease for the inhibitor X 300nM (Figure 25). 
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Figure 24: Representative pictures of adult DRG cultures stained for βIII-tubulin. A. DRG cultures in 0,1% 
DMSO (control); B. DRG cultures treated with inhibitor X 30nM; C. DRG cultures treated with inhibitor X 
300nM. 
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Figure 25: Neurite outgrowth of adult DRG neurons grown in the absence (control) or presence of inhibitor 
X (30nM and 300nM). The results are expressed as mean±sem. Two-tailed Student’s t test with p<0,05 (*). 
 
For the inhibitor VII, representative pictures are shown in Figure 26. In this case, the 
percentage of cells with neurites increases with the lowest dose of inhibitor and 
decreases with the higher dose, in comparison with the control. In addition, there is a 
decrease of the number of segments and total length from the control to the highest 
concentration of inhibitor. On the other hand, the length of the longest neurite is raised 
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for the lowest dose of inhibitor VII (Figure 27). Our results suggest that inhibitor VII is 
promoting the conditioning effect (not only by increasing the percentage of cells with 
neurites but also by increasing elongation). However, in order to confirm this result we 
will repeat this experiment in the future and we will perform Western blotting to assess 
the phosphorylation status of GSK3β. 
 
 
Figure 26: Representative pictures of adult DRG cultures stained for βIII-tubulin. A. DRG cultures in 
0,05%DMSO (control); B. DRG cultures treated with inhibitor VII 1µM; C. DRG cultures treated with inhibitor 
VII 10µM. 
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Figure 27: Neurite outgrowth of adult DRG neurons grown in the absence (control) or presence of inhibitor 
VII (1µM and 10µM). The results are expressed as mean±sem. Two-tailed Student’s t test with p<0,05 (*). 
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7. Identification of the mechanism responsible for the modulation of Y216 
phosphorylation 
 
The third part of this work consisted on designing strategies to shed light on the kinases 
responsible for GSK3β(Y216) phosphorylation. Two strong candidates were the tyrosine 
kinase Pyk2 and Fyn, described in the literature as potential GSK3β regulators by Y216 
phosphorylation. We performed Western blotting of Pyk2 in extracts both from spinal 
cord and DRG, and we could not find this kinase in any of them (data not shown). In 
parallel, we also performed DRG neuron cultures from animals with spinal cord injury 
transfected with a kinase dead construct of Pyk2 (Pyk2KD). The percentage of cells with 
neurites is smaller for the Pyk2KD transfected cells. Regarding the length of the longest 
neurite, this parameter was similar for the control and Pyk2KD transfected cells (Figure 
28). We suppose that these results together with the Western blot of Pyk2 indicate that 
this kinase does not play a fundamental role in GSK3β modulation. 
 
 
 
 
 
 
Figure 28: Neurite outgrowth of DRG neurons from animals with SCI transfected with EGFP or Pyk2KD. The 
results are expressed as mean±sem. Two-tailed Student’s t test with p<0,05 (*). 
 
In respect to Fyn, our results showed that in the spinal cord, the inactive form of this 
kinase pFyn(Y529) is increased after conditioning lesion in comparison with SCI only 
(Figure 29). This suggests that this tyrosine kinase might be a strong candidate for 
GSK3β(Y216) phosphorylation as an increase in the inactive form of the kinase after CL 
correlates with the observed decrease in pGSK3β(Y216). 
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Figure 29: Western blot analysis (A) and respective quantification (B) of the relative amount of pFyn(Y529) 
in spinal cord extracts of spinal cord injury (SCI) and conditioning lesion (CL) animals. Results are presented 
as mean±sem. Two-tailed Student’s t test with p<0,05 (*). 
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8. In vivo analysis of the role of GSK3β in CNS regeneration 
 
Based on our observations, inactivation of GSK3β in vivo could mimic the conditioning 
lesion model and promote regeneration after spinal cord injury. However, as described 
previously, controversy exists regarding the role of GSK3β modulation in CNS 
regeneration. While Dill and coworkers consider that GSK3β inactivation is pivotal for 
axonal outgrowth, Alabed et al suggest that this inactivation through S9 phosphorylation 
causes neurite retraction instead. In order to better understand the contribution of 
GSK3β to CNS regeneration in vivo we used the GSK3βS9A knockin mouse model. The use 
of these mice allows us to definitely clarify the role of pS9 in GSK3β regulation of axonal 
growth. We started by performing neurite outgrowth assays using both uninjured (Un) 
and conditioned DRG neurons (cDRG). Neurite outgrowth from adult uninjured DRG 
neurons is short and highly branched, whereas DRG neurons conditioned by prior 
axotomy in vivo are able to extend long and/or un-branched neurites within the first day 
in culture [60]. To mimetize the conditioning effect we trypsinized DRG neurons after 1 
day in culture. In Figure 30, representative pictures for the experiment can be seen. In the 
case of DRG neurons from WT animals we observed an increase in the percentage of cells 
with neurites and a significant decrease in the branching after conditioning (WT cDRG). 
However, contrarily to what is commonly observed in the conditioning effect, no increase 
of neurite length was observed in the WT conditioned (cDRG) in comparison with the WT 
uninjured (Un) DRG (Figure 31). In the case of the DRG from GSK3βS9A KI animals, a 
similar situation to WT animals occurred (Figure 31) which suggests that S9 
phosphorylation is not required for the conditioning effect. Moreover, in the case of 
uninjured DRG neurons no differences in neurite outgrowth were observed between WT 
and GSK3βS9A KI mice. These results show that regulation of GSK3β activity by S9 
phosphorylation is not relevant for the role of the kinase in axonal growth. 
50 
 
 
50 μm
50 μm
50 μm
50 μm
 
Figure 30: Representative pictures of DRG cultures stained for βIII-tubulin. A. DRG cultures from WT 
uninjured animals (WT Un); B. DRG cultures treated with trypsin from WT animals (WT cDRG); C. DRG 
cultures from GSK3βS9A knockin animals (KI Un); D. DRG cultures treated with trypsin from GSK3βS9A 
knockin animals (KI cDRG). 
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Figure 31: Neurite outgrowth of DRG neurons from WT and GSK3βS9A knockin (KI) animals in the absence 
(Un) or presence of trypsin (cDRG). The results are expressed as mean±sem. Two-tailed Student’s t test with 
p<0,05 (*). 
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Discussion and Conclusions 
 
It has been described that peripheral conditioning lesion switches DRG neurons to an 
active growth state, indicating that injury signals traveling retrogradely from the 
peripheral lesion site to the cell body can enhance the intrinsic growth capacity of the 
neurons [4]. Previously in our laboratory, two proteomic approaches, Kinexus and iTRAQ 
revealed several proteins belonging to cytoskeleton remodeling as being differentially 
regulated following conditioning lesion in DRG extracts. Among those proteins was 
GSK3β, a serine-threonine kinase which is a key regulatory enzyme in the nervous system. 
GSK3β emerged as a key player in the conditioning effect, as not only the kinase, but also 
its effectors and substrates were differentially regulated in the conditioning lesion model. 
As predicted by our proteomic data and validated by Western blotting, the conditioning 
lesion triggers a reduction in GSK3β activity in the DRG which might underlie the gain of 
regenerative capacity in this model.  
GSK3β is involved in axonal regeneration locally regulating the cytoskeleton dynamics of 
the growth cone. In the injury site, after lesion in the spinal cord, a decrease of the levels 
of S9 phosphorylation of GSK3β can be seen. After conditioning lesion, S9 
phosphorylation levels do not show any difference in comparison with spinal cord injury 
alone. Previously it has been described that after spinal cord lesion the levels of 
pGSK3β(S9) do not vary in the lesion site but that these levels increase after treatment 
with the GSK3β inhibitor lithium chloride, leading to a gain of regenerative capacity [3]. 
Interestingly, in our model, axonal regeneration in the spinal cord is achieved by a 
decrease in GSK3β activity through downregulation of Y216 phosphorylation promoted by 
the conditioning lesion. These results point to a regulatory role of tyrosine 
phosphorylation of GSK3 which has not been addressed in the context of axonal 
regeneration. In the literature it is mostly described the mechanism of GSK3β inhibition 
through S9 phosphorylation despite the importance of Y216 residue. Y216 is conserved 
among all GSK3 homologues isolated so far across very distinct species suggesting a 
critical role for this phosphorylation [61]. Moreover, some studies doubted the 
importance of  GSK3β(S9) phosphorylation, claiming that GSK3 inhibition regulating 
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neuronal polarization is not initiated by Akt phosphorylation of S9 [53]. In fact, not only 
S9 phosphorylation but also Y216 dephosphorylation of GSK3β was shown to be 
important for the extracellular signal-dependent regulation of GSK3β activity; treatment 
of Chinese hamster ovary cells overexpressing the human insulin receptor (CHO-IR) with 
insulin, induced inactivation and tyrosine dephosphorylation of GSK3β both in cells 
expressing GSK3βWT or cells expressing a truncated form of GSK3β where the N-terminal 
nine aminoacids were deleted [62]. 
Based on the decrease observed of GSK3 activity after conditioning lesion we 
determined the levels of the kinase substrates, CRMP2 and MAP1b, in the spinal cord 
injury site. In respect to CRMP2, as described in the literature, this protein has two 
isoforms: CRMP2A and CRMP2B which differ in molecular weight [59]. We observed 
decreased levels of pCRMP2A(T509/514) after conditioning lesion that can be correlated 
with the decrease in GSK3 activity. Our results show a decrease in CRMP2 
phosphorylation which is not related with an increase in the levels of pGSK3β(S9) but with 
a decrease of Y216 phosphorylation. Regarding MAP1b, we observed a rise of 
pMAP1b(T1265) phosphorylation after conditioning lesion in the injury site which, 
although not in agreement with a lower GSK3β activity, is in accordance with a higher 
regenerative capacity after conditioning. Our results are in agreement with the 
hypothesis that inactivation at the growth cone of GSK3 promotes an optimal 
microtubule assembly for axonal growth by blocking phosphorylation of CRMP2 and 
promoting phosphorylation of MAP1b [47]. 
In the DRG, our iTRAQ results showed a decrease in the levels of total CRMP2 (validated 
by Western blot) and MAP1b. Although this issue was not addressed in this project, this 
decrease in the DRG may indicate that the proteins are being increasingly transported to 
the spinal cord injury site after conditioning. 
The role for Y216 phosphorylation in the conditioning effect was confirmed by the 
observation that when conditioned DRGs are treated with the serum-borne lipid mediator 
lysophosphatidic acid (LPA), which increases the phosphorylation of Y216, the 
conditioning effect is attenuated which is in accordance with an inhibitory role of 
pGSK3β(Y216) in axonal regeneration. In fact, it has been described that treating 
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neuroblastoma cells with LPA causes GSK3β(Y216) phosphorylation and consequently 
neurite retraction [54]. Consistent with this finding, it was shown that after cerebral 
ischemia, GSK3β phosphorylation at Y216 is increased in neurons vulnerable to apoptosis 
suggesting that this phosphorylation site can be an alternative mechanism by which cell 
insults lead to death [63]. 
Further analysis of GSK3β modulation through Y216 phosphorylation in axonal 
regeneration showed us that neurite extension is decreased when Y216 can not be 
phosphorylated, as is the case of DRG neurons transfected with the EGFP-GSK3βY216F 
construct. Although this mutant has previously been described as containing a specific 
activity of 10% of WTGSK3β [61], we observed that overexpression of GSK3βY216F in DRG 
neurons has the same effect of overexpression of the kinase-dead GSK3βK85M mutant 
[45]. This in accordance with the fact that GSK3β requires a minimal activity in order to 
phosphorylate MAP1b.  
Taking into account the hypothesis that GSK3β inhibitors treatment might be a better 
strategy to disclose the role of Y216 phosphorylation in axonal regeneration, we analysed 
the effect of different GSK3β inhibitors in the neurite outgrowth of adult DRG neurons 
with the goal to analyse in parallel whether that effect is related to regulation of S9 or 
Y216 phosphorylation. Several authors tested different GSK3β inhibitors in DRG neuronal 
cultures but the phosphorylation status of GSK3β was not verified. Adult DRG neurons 
were treated with two distinct concentrations (low and high dose) for each of three 
different GSK3 β inhibitors: inhibitor SB415286, inhibitor X and inhibitor VII. The lowest 
concentration would correspond to a partial inactivation of GSK3β, which seems ideal for 
neuronal growth, and in contrary, the highest concentration would lead to the enzyme 
total inactivation that prevents axon growth [45]. For the inhibitor SB415286, no 
significant difference was obtained in the neurite outgrowth between the control and the 
lowest dose, unlike Dill and coworkers that observed an increased axon length in the DRG 
neurons with a low concentration of inhibitor [3]. On the other hand, a decrease of the 
axonal length can be observed when DRG neurons are treated with the high 
concentration of inhibitor in agreement with Dill [3]. In the case of the inhibitor X, which 
shows high GSK3 specificity, no significant differences were seen, contrarily to Kim and his 
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collaborators that observed a disorder of axon polarity at lower concentrations of 
inhibitor. They also observed that inactivating GSK3 with a high dose of GSK3 inhibitor 
causes a decreased axonal regeneration in immature and adult conditioned DRG neurons 
[45]. Concerning inhibitor VII, we observed an increase in the length of the longest 
neurite when neurons are treated with the lowest concentration. Regarding the highest 
concentration, axonal growth is precluded in comparison with the control, which might 
be due to the total inactivation of the enzyme. This GSK3 inhibitor may be useful for 
studying the role of Y216 phosphorylation as treatment of cortical neurons with inhibitor 
VII for 24 hours decreases Y216 phosphorylation, without significant variation in 
pGSK3β(S9) levels [49]. However, in order to confirm this result, we will need to repeat 
this experiment and in parallel assess the phosphorylation status of GSK3β. 
The third part of this project was intended to unravel the kinases responsible for 
GSK3β(Y216) phosphorylation. In Dictyostelium there is an increase in tyrosine 
phosphorylation mediated by the ZAK1 kinase. Although no mammalian orthologs of 
ZAK1 exist [64], three putative candidates are described in the literature: Pyk2 [54], Fyn 
[65] and Csk [66]. In what concerns Pyk2, this kinase was not found in the spinal cord by 
Western blot although it is described that Pyk2 is highly expressed in the developing 
nervous system as well as adult brain [54]. In a model of brain degeneration, Fyn has been 
associated with Y216 phosphorylation and consequent participation in proapoptosis [63]. 
Our results suggest that Fyn kinase may be a strong candidate for GSK3β(Y216) 
phosphorylation, as an increase of the Fyn inactive form pFyn(Y529) is observed after 
conditioning lesion in the spinal cord. In order to confirm that the decrease of Y216 
phosphorylation of GSK3β is due to the inactivation of Fyn, we will analyse whether this 
kinase co-immunoprecipitates with GSK3β. Moreover, similarly to what was described for 
the overexpression of GSK3βY216F, transfection of DRG neurons with a Fyn kinase dead 
mutant will be performed. This will clarify the consequences in neurite outgrowth of 
downregulating Y216 by inhibiting this tyrosine kinase. Nonetheless, the Y216 
phosphorylation mechanism could be an autophosphorylation event as described 
previously [55]. In fact, in agreement with the autophosphorylation model, it has been 
observed that a kinase-negative mutant of GSK3 is not tyrosine phosphorylated and on 
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the other hand, GSK3 produced in E.coli is tyrosine phosphorylated [62]. In this case, 
putative GSK3β phosphatases should be investigated as this might represent the GSK3β 
regulatory event. Despite the fact that protein phosphatases, including PP1 and PP2A 
have been implicated in GSK3 serine dephosphorylation [49], so far protein phosphatases 
capable of dephosphorylating GSK3(Y216) have not been identified.  
Finally, we used the GSK3βS9A KI mice [57], where GSK3β activity cannot be regulated by 
pGSK3β(S9) and as such the role of modulating this particular residue could be definitively 
elucidated. Our neurite outgrowth measurement results did not show any differences 
between WT and GSK3βS9A KI animals. According to Dill and coworkers, GSK3β 
inactivation through S9 phosphorylation leads to increased neurite outgrowth of DRG 
neurons on myelin and CSPG substrates and stimulates growth of corticospinal tract 
fibers around the site of SCI [3]. On the other hand, Alabed et al claim that S9 
phosphorylation causes axonal growth inhibition in rat cerebellar and DRG neurons [56]. 
Our results show that regulation of S9 phosphorylation does not have an effect in the 
growth of adult DRG neurons. Regarding the conditioning effect (obtained by treatment 
with trypsin), we observed the same effect in both DRG neurons from WT and GSK3βS9A 
KI mice. Our results show that the conditioning effect may occur independently of S9 
phosphorylation. As future work, we plan to repeat this experiment by using conditioned 
DRGs from animals with axotomy in the sciatic nerve. Also, we will perform in vitro 
neurite outgrowth assays in DRG neurons plated in inhibitory substrates. Moreover, we 
intend to measure pGSK3(Y216) levels as well as  levels of phosphorylated CRMP2 and 
MAP1b in the GSK3βS9A KI mice. In addition, to assess regeneration in vivo in the 
GSK3βS9A KI mice, we will perform SCI or conditioning lesion and assess regeneration of 
dorsal column axons by quantification of retrograde tracing with cholera toxin B.  
Together our results suggest that GSK3β inactivation (through a decrease in Y216 
phosphorylation) leads to axonal regeneration in the spinal cord which is in agreement 
with several authors [3, 45]. However, as already referred to, there is still some 
controversy regarding this mechanism, being that some authors claim that GSK3β 
inactivation leads to axonal retraction instead, through direct S9 phosphorylation by MAIs 
[56]. This controversy derives mainly from experiments assessing pharmacological 
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inhibition of GSK3β. In fact, Dill et al showed that treatment of adult DRG neuronal 
cultures with 3mM lithium chloride or 7,5μM SB415286 enhanced axonal length [3]. On 
the other hand, Alabed et al observed a decreased neurite outgrowth when treating adult 
DRG neurons with the GSK3 inhibitor 6-bromoindirubin-3’-oxime (inhibitor X) [56]. We 
believe that the dose of the inhibitor X used in this study (300nM) provoked the complete 
inhibition of kinase activity leading to dephosphorylation of both primed and unprimed 
GSK3β substrates resulting in axonal growth impairment as Kim et al concluded when 
treating embryonic DRG neurons with high doses of inhibitor [45]. As such, we believe 
that the difference in results obtained with the pharmacological inhibition of GSK3β may 
be related to a question of dosage. 
As future work we plan to confirm the role of GSK3β in CNS regeneration in vivo using 
additional transgenic GSK3β mouse models namely, GSK3β knockout (KO) heterozygous 
mice [67], and the floxed GSK3β mice [68]. In heterozygous GSK3βKO mice the kinase 
activity levels are partially reduced. The floxed GSK3β mice will be crossed with Thy1-cre 
mice [69] in order to specifically ablate GSK3β activity in axons. The conditional knockout 
strategy will be used as it was shown that homozygous knockout mice targeting GSK3β 
die either at mid- or late-embryonic stages with none surviving postnatally [67]. It is 
important to mention that none of these GSK3β transgenics has ever been used to assess 
axonal regeneration in vivo. 
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